Evidence map›Paper›PMID 35867722›Full record

ArticlePLoS pathogens2022

The role of CD101-expressing CD4 T cells in HIV/SIV pathogenesis and persistence.

Zachary Strongin, Timothy N Hoang, Gregory K Tharp, Andrew R Rahmberg, Justin L Harper, Kevin Nguyen, Lavinia Franchitti, Barbara Cervasi, Max Lee, Zhan Zhang and 7 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  3. BeyondFrontiers in genetics · 2026
    Review
  4. Article
  5. Review
  6. Advances in Single-Cell Sequencing for Infectious Diseases: Progress and Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  7. Distinct SIV-specific CD8Nature immunology · 2024
    Article
  8. [Immunological Causes of Oral Manifestations of HIV Infection: A Literature Review].Revista cientifica odontologica (Universidad Cientifica del Sur)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Zachary StronginDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University; Atlanta, Georgia, United States of America.
Timothy N HoangDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University; Atlanta, Georgia, United States of America.
Gregory K TharpDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University; Atlanta, Georgia, United States of America.
Andrew R RahmbergBarrier Immunity Section, Laboratory of Viral Diseases, NIAID, NIH; Bethesda, Maryland, United States of America.
Justin L HarperDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University; Atlanta, Georgia, United States of America.
Kevin NguyenDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University; Atlanta, Georgia, United States of America.
Lavinia FranchittiDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University; Atlanta, Georgia, United States of America.
Barbara CervasiFlow Cytometry Core, Emory Vaccine Center, Emory University; Atlanta, Georgia, United States of America.
Max LeeVaccine Research Center, National Institutes of Health; Bethesda, Maryland, United States of America.
Zhan ZhangDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University; Atlanta, Georgia, United States of America.
Eli A BoritzVaccine Research Center, National Institutes of Health; Bethesda, Maryland, United States of America.
Guido SilvestriDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University; Atlanta, Georgia, United States of America.
Vincent C MarconiDivision of Infectious Diseases, Emory University School of Medicine; Atlanta, Georgia, United States of America.
Steven E BosingerDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University; Atlanta, Georgia, United States of America.
Jason M BrenchleyBarrier Immunity Section, Laboratory of Viral Diseases, NIAID, NIH; Bethesda, Maryland, United States of America.
Deanna A KulpaDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University; Atlanta, Georgia, United States of America.
Mirko PaiardiniDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University; Atlanta, Georgia, United States of America.ORCID 0000-0002-7276-3600
Oregon National Primate Research Center · USEmory University · USNational Institutes of Health · USOffice of Extramural Research · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
Mechanisms of Immune Activation and Disease Progression in Animal ModelsZIAAI001029 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BRENCHLEY, JASON · 2009 to 2025
$28.2M
Viral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Matthew Ryan Gardner · 2018 to 2026
$17.5M
HIV persistence in vivoZIAAI005131 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BORITZ, ELI · 2017 to 2025
$14.5M
SPF Breeding Colonies at the Yerkes NPRCU24OD011023 · OD · EMORY UNIVERSITY · PI COHEN, JOYCE KIMBERLY · 2012 to 2017
$8.2M
Harnessing IL-10 in cART treated SIV infected macaques to restore immunity and to eradicate HIVR37AI141258 · NIAID · EMORY UNIVERSITY · PI Rafick Pierre Sekaly · 2018 to 2026
$7.8M
Immune based interventions for HIV eradicationR01AI116379 · NIAID · EMORY UNIVERSITY · PI PAIARDINI, MIRKO · 2015 to 2019
$4.2M
Targeting Cytolytic Cells to Lymphoid Sites of HIV Persistence.R33AI116171 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI LEDERMAN, MICHAEL MARCEL, PAIARDINI, MIRKO · 2016 to 2018
$1.5M
NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI116379NIAID NIH HHS R33 AI116171NIAID NIH HHS R37 AI141258NIAID NIH HHS UM1 AI164562NIH HHS P51 OD011132NIH HHS U24 OD011023NIH HHS U42 OD011023
6 · The paper itself

Abstract

Despite the advent of effective antiretroviral therapy (ART), human immunodeficiency virus (HIV) continues to pose major challenges, with extensive pathogenesis during acute and chronic infection prior to ART initiation and continued persistence in a reservoir of infected CD4 T cells during long-term ART. CD101 has recently been characterized to play an important role in CD4 Treg potency. Using the simian immunodeficiency virus (SIV) model of HIV infection in rhesus macaques, we characterized the role and kinetics of CD101+ CD4 T cells in longitudinal SIV infection. Phenotypic analyses and single-cell RNAseq profiling revealed that CD101 marked CD4 Tregs with high immunosuppressive potential, distinct from CD101- Tregs, and these cells also were ideal target cells for HIV/SIV infection, with higher expression of CCR5 and α4β7 in the gut mucosa. Notably, during acute SIV infection, CD101+ CD4 T cells were preferentially depleted across all CD4 subsets when compared with their CD101- counterpart, with a pronounced reduction within the Treg compartment, as well as significant depletion in mucosal tissue. Depletion of CD101+ CD4 was associated with increased viral burden in plasma and gut and elevated levels of inflammatory cytokines. While restored during long-term ART, the reconstituted CD101+ CD4 T cells display a phenotypic profile with high expression of inhibitory receptors (including PD-1 and CTLA-4), immunsuppressive cytokine production, and high levels of Ki-67, consistent with potential for homeostatic proliferation. Both the depletion of CD101+ cells and phenotypic profile of these cells found in the SIV model were confirmed in people with HIV on ART. Overall, these data suggest an important role for CD101-expressing CD4 T cells at all stages of HIV/SIV infection and a potential rationale for targeting CD101 to limit HIV pathogenesis and persistence, particularly at mucosal sites.

Indexed as

HIV InfectionsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsCD4-Positive T-LymphocytesHumansMacaca mulatta

Identifiers

PMID35867722
PMCPMC9348691
OpenAlexW4286587097

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.